Immunotherapy: an emerging modality to checkmate brain metastasis

Molecular Cancer

Review

Parvez Khan¹  Aatiya Ahmad¹  Asad Ur Rehman¹  Mohd Wasim Nasser²  Surinder Kumar Batra³ 

[1] Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, NE-68198, Omaha, USA;Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, NE-68198, Omaha, USA;Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, 68198, Omaha, NE, USA;Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, NE-68198, Omaha, USA;Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, 68198, Omaha, NE, USA;Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, NE-68198, Omaha, USA;

关键词: Immunotherapy;    Brain metastases;    Tumor microenvironment;    Anticancer immunity;    Immune checkpoint inhibitors;   

DOI  :  10.1186/s12943-023-01818-7

 received in 2023-04-03, accepted in 2023-07-06,  发布年份 2023

来源: Springer

【 摘 要 】

The diagnosis of brain metastasis (BrM) has historically been a dooming diagnosis that is nothing less than a death sentence, with few treatment options for palliation or prolonging life. Among the few treatment options available, brain radiotherapy (RT) and surgical resection have been the backbone of therapy. Within the past couple of years, immunotherapy (IT), alone and in combination with traditional treatments, has emerged as a reckoning force to combat the spread of BrM and shrink tumor burden. This review compiles recent reports describing the potential role of IT in the treatment of BrM in various cancers. It also examines the impact of the tumor microenvironment of BrM on regulating the spread of cancer and the role IT can play in mitigating that spread. Lastly, this review also focuses on the future of IT and new clinical trials pushing the boundaries of IT in BrM.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2023_38_Article_IEq181.gif

41116_2023_38_Article_IEq133.gif

41116_2023_38_Article_IEq36.gif

Fig. 10